<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440478</url>
  </required_header>
  <id_info>
    <org_study_id>12322</org_study_id>
    <secondary_id>H8Y-EW-HBBX</secondary_id>
    <secondary_id>2011-003215-36</secondary_id>
    <nct_id>NCT01440478</nct_id>
  </id_info>
  <brief_title>The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects</brief_title>
  <official_title>Impact of Variations in Urinary pH on the Pharmacokinetics of LY2140023 and LY404039 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to explore the effect of increased and decreased urinary pH on the&#xD;
      single pharmacokinetic (PK) dose of LY2140023 and its active metabolite LY404039. All&#xD;
      participants will receive the three treatments in a randomized order.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: area under the concentration versus time curve (AUC) of LY2140023 and LY404039</measure>
    <time_frame>Predose and up to 24 hours post dose after LY2140023 dosing for each of the 3 treatment periods</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: maximum observed drug concentration (Cmax) of LY2140023 and LY404039</measure>
    <time_frame>Predose and up to 24 hours post dose after LY2140023 dosing for each of the 3 treatment periods</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in urine pH</measure>
    <time_frame>Predose and up to 24 hours post dose after LY2140023 dosing for each of the 3 treatment periods</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>LY2140023 + ammonium chloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 g of ammonium chloride administered orally every 3 hours for 33 hours (totaling 12 doses) in combination with a single 80 mg dose of LY2140023 administered orally 17 hours after first dose of ammonium chloride (acidified urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2140023 + sodium bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 g of sodium bicarbonate administered orally every 4 hours for 32 hours (totaling 9 doses) in combination with a single 80 mg dose of LY2140023 administered orally 18 hours after first dose of sodium bicarbonate (alkalized urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2140023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 80 mg dose of LY2140023 administered orally (normal urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2140023</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2140023</arm_group_label>
    <arm_group_label>LY2140023 + ammonium chloride</arm_group_label>
    <arm_group_label>LY2140023 + sodium bicarbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ammonium chloride</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2140023 + ammonium chloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium bicarbonate</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2140023 + sodium bicarbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  are overtly healthy males or females, as determined by medical history and physical&#xD;
             examination&#xD;
&#xD;
          -  female subjects of childbearing potential, who test negative for pregnancy at&#xD;
             screening. Male subjects/female subjects of childbearing potential/female subjects who&#xD;
             have been sterilized by tubal ligation and their partners will be required to use a&#xD;
             condom (male condom or female condom) used in conjunction with spermicidal gel, foam,&#xD;
             cream, film, or suppository from the time of screening (female subjects) or dosing&#xD;
             (male subjects) until 3 months after the last dose of investigational product. Male&#xD;
             subjects with female partners of childbearing potential and female subjects of&#xD;
             childbearing potential will be requested to use an additional highly effective form of&#xD;
             contraception from the first dosing occasion until 3 months after the last dose of&#xD;
             investigational product. The additional method of contraception can be any of the&#xD;
             following: diaphragm or cervical vault cap used in conjunction with spermicidal gel,&#xD;
             foam, cream, film, or suppository; male sterilization, with the appropriate post&#xD;
             vasectomy documentation of the absence of sperm in the ejaculate, or for female&#xD;
             subjects the vasectomized male partner should be the sole partner for that subject;&#xD;
             true abstinence (this must be due to subject's lifestyle choice; placement of an&#xD;
             effective hormonal intrauterine device (IUD) (i.e. Mirena Coil) (steel or copper IUDs&#xD;
             are not acceptable); or established use of oral, injected, or implanted hormonal&#xD;
             methods of contraception&#xD;
&#xD;
          -  female subjects who are of non childbearing potential i.e. post menopausal or&#xD;
             permanently sterile following hysterectomy, bilateral salpingectomy or confirmed tubal&#xD;
             occlusion (not tubal ligation). Postmenopausal is defined as at least 1 year post&#xD;
             cessation of menses (without an alternative medical cause) with follicle stimulating&#xD;
             hormone (FSH) ≥40 mIU/mL&#xD;
&#xD;
          -  have a body mass index (BMI) of 19 to 32 kg/m^2, inclusive, at the time of screening&#xD;
&#xD;
          -  have clinical laboratory test results within normal reference range for the population&#xD;
             or investigator site, or results with acceptable deviations that are judged to be not&#xD;
             clinically significant by the investigator&#xD;
&#xD;
          -  have venous access sufficient to allow for blood sampling&#xD;
&#xD;
          -  are reliable and willing to make themselves available for the duration of the study&#xD;
             and are willing to follow study procedures&#xD;
&#xD;
          -  have given written informed consent approved by Lilly and the chosen ethical review&#xD;
             board (ERB)&#xD;
&#xD;
          -  are willing to adhere to dietary requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  are currently enrolled in, have completed or discontinued within the last 90 days&#xD;
             from, a clinical trial involving an investigational product; or are concurrently&#xD;
             enrolled in any other type of medical research judged not to be scientifically or&#xD;
             medically compatible with this study&#xD;
&#xD;
          -  have known allergies to LY2140023, LY404039, ammonium chloride, sodium bicarbonate,&#xD;
             related compounds, or any components of the formulation&#xD;
&#xD;
          -  are persons who have previously received the investigational product in this study,&#xD;
             withdrawn from this study or any other study investigating LY2140023 or LY404039&#xD;
&#xD;
          -  have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the&#xD;
             investigator, increases the risks associated with participating in the study&#xD;
&#xD;
          -  have an abnormality in the serum chemistry of calcium, sodium, magnesium, or&#xD;
             potassium, that, in the opinion of the investigator, increases the risks associated&#xD;
             with participating in the study&#xD;
&#xD;
          -  have an abnormal supine and standing blood pressure or pulse rate, as determined by&#xD;
             the investigator&#xD;
&#xD;
          -  have a history or presence of cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, hematological, or neurological disorders capable of&#xD;
             significantly altering the absorption, metabolism, or elimination of drugs; of&#xD;
             constituting a risk when taking the study medication; or of interfering with the&#xD;
             interpretation of data&#xD;
&#xD;
          -  have evidence of significant active neuropsychiatric disease (for example, manic&#xD;
             depressive illness, schizophrenia, depression)&#xD;
&#xD;
          -  have increased risk of seizures based on a history of:&#xD;
&#xD;
               -  one or more seizures (except for a single simple febrile seizure [lacking&#xD;
                  focality and lasting less than 15 minutes, not associated with a central nervous&#xD;
                  system (CNS) infection or severe metabolic disturbance] as a child between ages 6&#xD;
                  months to 5 years)&#xD;
&#xD;
               -  head trauma with loss of consciousness or a post concussive syndrome within 1&#xD;
                  year or lifetime history of head trauma with persistent neurological deficit&#xD;
                  (focal or diffuse)&#xD;
&#xD;
               -  CNS infection, uncontrolled migraine or transient ischemic attack (TIA) within 1&#xD;
                  year; stroke with persistent neurological deficit (focal or diffuse),&#xD;
                  uncontrolled migraine is defined as migraine attacks that produce headache&#xD;
                  lasting up to 72 hours and are often accompanied by associated symptoms (nausea,&#xD;
                  photophobia, and phonophobia) that impair well-being and disrupt social&#xD;
                  functioning. TIA is defined as &quot;mini-stroke&quot; caused by temporary disturbance of&#xD;
                  blood supply to an area of the brain, which results in a sudden, brief decrease&#xD;
                  in brain function&#xD;
&#xD;
               -  CNS infection with persistent neurological deficit (focal or diffuse)&#xD;
&#xD;
               -  brain surgery&#xD;
&#xD;
               -  electroencephalogram (EEG) with paroxysmal (epileptiform) activity (isolated&#xD;
                  spikes waves, repetitive bursts of sharp waves, paroxysmal activity, frank&#xD;
                  seizures, spike-wave complexes, or sharp-slow wave complexes, or as locally&#xD;
                  defined)&#xD;
&#xD;
               -  brain structural lesion, including developmental abnormalities, as determined by&#xD;
                  examination or imaging studies (does not include hydrocephalus unless treated by&#xD;
                  shunt or resulting in neurological deficits)&#xD;
&#xD;
          -  show evidence of known substance dependence or abuse within 6 months prior to the&#xD;
             study (according to Diagnostic and Statistical Manual of Mental Disorders [DSM IV]&#xD;
             diagnosis), or regularly use known drugs of abuse and/or show positive findings on&#xD;
             urinary drug screening&#xD;
&#xD;
          -  show evidence of human immunodeficiency virus (HIV) infection and/or positive human&#xD;
             HIV antibodies&#xD;
&#xD;
          -  show evidence of hepatitis C and/or positive hepatitis C antibody&#xD;
&#xD;
          -  show evidence of hepatitis B and/or positive hepatitis B surface antigen&#xD;
&#xD;
          -  are women with a positive pregnancy test or women who are lactating&#xD;
&#xD;
          -  intend to use over the counter (excluding most vitamin/mineral supplements but&#xD;
             including herbal remedies/health supplements or prescription medication (excluding&#xD;
             paracetamol, oral contraceptives and hormone replacement therapy) within 14 days prior&#xD;
             to dosing of LY2140023. If this situation arises, inclusion of an otherwise suitable&#xD;
             subject may be at the discretion of the investigator in consultation with the Lilly&#xD;
             Clinical Pharmacologist (CP) or designee&#xD;
&#xD;
          -  have donated blood of more than 500 mL within 3 months prior to screening&#xD;
&#xD;
          -  have an average weekly alcohol intake that exceeds 28 units per week (males up to age&#xD;
             65) and 21 units per week (females), or are unwilling to stop alcohol consumption for&#xD;
             the duration of the study (1 unit equals 12 oz or 360 mL of beer; 5 oz or 150 mL of&#xD;
             wine; 1.5 oz or 45 mL of distilled spirits)&#xD;
&#xD;
          -  have a clinical significant abnormality in the neurological examination&#xD;
&#xD;
          -  subjects judged prior to randomization to be at suicidal risk by the investigator&#xD;
&#xD;
          -  subjects who are unwilling to refrain from tobacco or nicotine containing products&#xD;
             while in the Clinical Research Unit (CRU) or are unable to abide by the CRU&#xD;
             restrictions&#xD;
&#xD;
          -  history of, in the opinion of the investigator, excessive methylxanthine use within&#xD;
             previous 6 months, such as &gt;6 cups of coffee (or equivalent) per day&#xD;
&#xD;
          -  show evidence of active renal disease (for example, diabetic renal disease, polycystic&#xD;
             kidney disease) or creatinine clearance (CrCL) less than 80 mL/min (as calculated by&#xD;
             the Cockcroft Gault equation) Men: [(140 - age) * (weight in kg) * 1.23] / (serum&#xD;
             creatinine in µmol/L). Women: [(140 - age) * (weight in kg) * 1.04] / (serum&#xD;
             creatinine in µmol/L)&#xD;
&#xD;
          -  show evidence of pruritus or skin exfoliation&#xD;
&#xD;
          -  have an eosinophil count &gt;1.5 x 109/L&#xD;
&#xD;
          -  have creatine kinase (CK) &gt;5 x upper limit of normal (ULN)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>August 31, 2011</study_first_submitted>
  <study_first_submitted_qc>September 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2011</study_first_posted>
  <last_update_submitted>October 7, 2011</last_update_submitted>
  <last_update_submitted_qc>October 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <pending_results>
    <submitted>August 30, 2021</submitted>
    <returned>September 23, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

